{"id":128460,"name":"AMARIN PHARMA, INC.","slug":"amarin-pharma-inc","state":"NJ","country":"United States of America","description":"Manufacturing","totalSpending":1270000,"filings":24,"yearlySpending":[{"year":2018,"income":210000},{"year":2019,"income":400000},{"year":2020,"income":320000},{"year":2021,"income":290000},{"year":2022,"income":30000},{"year":2024,"income":20000},{"year":2025,"income":0}],"issues":["HCR"],"firms":["KING & SPALDING LLP"],"lobbyists":["ALLISON KASSIR","DAVID FARBER","JEANNINE BENDER","MICHAEL ANDREWS","ALEXANDER (\"ANDER\") CRENSHAW","SCOTT DZIENGELSKI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Natl Institutes of Health (NIH)","White House Office","Health & Human Services, Dept of (HHS)","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["Advocacy on approval of triglyceride medications","Advocacy on approval of triglyceride medications","Advocacy on approval of triglyceride medications","Advocacy related to cardiovascular health and reduction of residual risk after statins","Advocacy related to cardiovascular health and reduction of residual risk after statins"],"years":[2018,2019,2020,2021,2022,2024,2025]}